Excellent read! Boiling it down to big companies being inherently structured for throughput, not efficiency really stuck with me.
The idea of a two-week NDA process not being seen as critical because these teams still still work on other drugs in the pipeline, and it's only when you have a single drug that you pay attention to every blocker, collaborate and bring processes in-house, and end up changing a hundred small things that all add up to a dramatically faster release.
Excellent read! Boiling it down to big companies being inherently structured for throughput, not efficiency really stuck with me.
The idea of a two-week NDA process not being seen as critical because these teams still still work on other drugs in the pipeline, and it's only when you have a single drug that you pay attention to every blocker, collaborate and bring processes in-house, and end up changing a hundred small things that all add up to a dramatically faster release.